Home » Stocks » GRPH

Graphite Bio, Inc. (GRPH)

Graphite Bio will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) n/a
Net Income (ttm) -87.94M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Graphite Bio, Inc. has filed to go public with an IPO on the NASDAQ.

2 weeks ago - SEC

About GRPH

Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Our next-generation gene editing platform allows us to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. We believe our approach could enable broad applications to transform human health, including directly correcting mutati... [Read more...]

Industry
Biological Products
IPO Date
Pending
CEO
Josh Lehrer, M.D.
Employees
27
Stock Exchange
NASDAQ
Ticker Symbol
GRPH
Full Company Profile

Financial Performance

Financial Statements